Understanding how KAT6A affects a type of blood cancer called acute myeloid leukemia.
Investigating the role of KAT6A in MLL-rearranged acute myeloid leukemia
This study is looking at a protein called KAT6A that might be stopping blood cells from developing properly in people with acute myeloid leukemia (AML), and by figuring out how to block this protein, researchers hope to find better treatments that help these cancer cells grow and mature like they should.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11072473 on NIH RePORTER |
What this research studies
This research investigates the role of KAT6A, a protein that may block the normal maturation of blood cells in acute myeloid leukemia (AML). By using advanced techniques like CRISPR, the researchers aim to identify how inhibiting KAT6A can promote the differentiation of leukemia cells, potentially leading to better treatment options. The study focuses on both MLL-rearranged and MLL-wild type AML, exploring how different therapies can reactivate the maturation processes of these cancer cells. Patients may benefit from new therapeutic strategies that target this mechanism to improve outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with MLL-rearranged or MLL-wild type acute myeloid leukemia.
Not a fit: Patients with other types of leukemia or those who do not have MLL-rearranged or MLL-wild type AML may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that help leukemia cells mature and reduce cancer proliferation.
How similar studies have performed: Previous research has shown promise in targeting epigenetic factors in AML, suggesting that this approach could lead to meaningful advancements in treatment.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Blanco, Mario Andres — University of Pennsylvania
- Study coordinator: Blanco, Mario Andres
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.